Wells Fargo lowered the firm’s price target on Varonis (VRNS) to $46 from $48 and keeps an Equal Weight rating on the shares. Shares of Varonis traded down after market close on mixed Q4 results. While the SaaS transition is accelerating, the impact from GenAI remains small and ARR growth is decelerating to just 15% in CY25, which does not yet warrant a premium valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNS: